DXS International PLCAQUIS: DXSP

DXS INTERNATIONAL PLC (AQSE: DXSP) Notificati...

· Issued by DXS International PLC

DXS INTERNATIONAL PLC (AQSE: DXSP) Notification of Director / PDMR Dealing

DXS INTERNATIONAL PLC

The Board of DXS International plc (the “Company” or “DXSP), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems, has received notification that on 11 November, Mr Bob Sutcliffe, the Chairman, purchased 50,000 Ordinary Shares in the Company at a price of 1.30p per share.

Following this transaction Mr Sutcliffe and his wife’s interest in DXS Ordinary Shares is 1,383,756 Ordinary Shares representing 2.16% of the issued share capital of the Company.

1Details of the person discharging managerial responsibilities / person closely associated
a)NameMr. Robert Sutcliffe
2Reason for the notification
a)Position/statusChairman
b)Initial notification /AmendmentInitial
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameDXS INTERNATIONAL PLC
b)LEI2138001R1KEUWTXEVJ44
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentOrdinary Shares of 0.33p each
Identification codeISIN GB00B2Q6HZ92
b)Nature of the transactionPurchase of shares
c)Price(s) and volume(s)
Price(s)Volume(s)
1.30p50,000
d)Aggregated information
- Aggregated volume
- Price
e)Date of the transaction11 November 2025
f)Place of the transactionAquis Stock Exchange

The Directors of DXS International plc accept responsibility for this announcement.

Contacts:

David Immelman
DXS International plc
www.dxs-systems.com
01252 719800
AQSE Corporate Broker and AQSE Corporate Advisor
Hybridan LLP
Claire Louise Noyce
020 3764 2341

Notes to Editors

About DXS:
DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively and which should significantly contribute towards the NHS achieving its projected efficiency savings.

Attachment

DXS International PLC on 6ix

Earlier from DXS International

Later from DXS International

All DXS International news releases